Name: A Standardized Liquid Biopsy Preanalytical Protocol for Downstream Circulating-Free DNA Applications (Video) | JoVE Journal
Uploaded: 2022-09-16T13:40:00.000+00:00
Duration: 5 min 26 s
Description: Learn a standardized liquid biopsy protocol for processing and storing blood samples for circulating free DNA applications in oncology research. This method reduces variability and enhances precision in clinical outcomes.

ai_agent_IP

ai_agent

maintenance

instantTrialDurationMinutes

isBiopharma

enableNewMyJoveSectionDesign

educationFeatures

seoMetaApi

ai_copilot_institution_blacklist

ai_chat_institution_blacklist

freeAccessWindow

ssoRoleCapture

scheduledMaintenanceBanner

joveLabsFeatures

disable_autoplay_for_bots

extended_trial_duration

5 minutes

playerTrialDesktop

We would like to thank the Biomedical Research Network in Cancer (CIBERONC) for their support and the following project grant: LB CIBERONC PLATFORM: CIBERONC platform for the standardization and promotion of liquid biopsy. PI Rodrigo Toledo, (CIBERONC), 2019-2021.

Prior ethical approval was obtained from participating centers before the extraction of blood samples. The following protocols for serum and plasma isolation were performed in accordance with the ethical principles for biomedical research.
NOTE: Prior considerations before beginning the protocol are provided here. Prior ethical approval is required for the use of human samples in biomedical research, with the corresponding informed consent. A class II biosafety cabinet is required to handle blood samples. A lab coat, protective gloves, and glasses should be worn throughout the procedure to avoid infection by blood-borne pathogens. A minimum of 30 min is required for the processing of serum samples. After blood extraction in tubes without anticoagulant, maintain at room temperature (RT) for 30-45 min to allow clot formation. A minimum of 40 min is required for plasma preparation, and samples should be processed within 4 h from the time of extraction when using ethylenediamine tetra-acetic acid (EDTA) tubes or within 24-48 h if using cell stabilizing collection tubes or specific cell-free DNA collection tubes. However, according to some manufacturers, the samples are stable for up to 2 weeks in these specialized tubes. It is important to check for hemolysis, which will give the plasma or serum fraction a reddish appearance. See the troubleshooting section for hemolyzed samples in the discussion.
1. Serum preparation for liquid biopsy studies
NOTE: Total time required to perform this step is 30 min (Figure 1).
<ol>
	<li>Extract 4-10 mL of blood in tubes containing no anticoagulant (red or red/gray-black cap) and maintain at RT for 30-45 min. Process these samples within 4 h from the time of extraction.</li>
	<li>Record the time and date of the sample extraction and the subject identification (ID) in an appropriately designed sample database.</li>
	<li>Wearing a lab coat, protective gloves and glasses, centrifuge the tube containing fresh blood at RT (15 &#176;C-25 &#176;C) for 10 min at 1,600 (&#177; 150) x g, with the maximum break applied.</li>
	<li>After centrifugation, carefully remove the tube from the centrifuge; the upper phase of serum supernatant will appear clear and yellowish (Figure 2). Check whether the sample shows signs of hemolysis (Figure 3) and record the presence of hemolysis when appropriate.</li>
	<li>In a class II biosafety cabinet, transfer the serum to collection tubes as 250 &#181;L aliquots. 
	NOTE: The volume of the aliquots must be adjusted to the study requirements.</li>
	<li>Immediately freeze the serum upright in a storage box at -80 &#176;C and record the time of sample storage.</li>
	<li>Verify that the samples were processed within the required 4 h time frame.</li>
</ol>
2. Plasma preparation for liquid biopsy studies
NOTE: The total time required to perform this step is 40 min (Figure 4).
<ol>
	<li>Extract 4-10 mL of blood in tubes containing ethylenediamine tetra-acetic acid (EDTA). Process the sampleswithin 4 h from the time of extraction.</li>
	<li>Record the time and date of the sample extraction and the subject ID in an appropriately designed sample database.</li>
	<li>Wearing a lab coat, protective gloves, and glasses, centrifuge the EDTA tube at RT (15 &#176;C-25 &#176;C) for 10 min at 1,600 (&#177; 150) x g, with the maximum break applied. 
	NOTE: Refer to the manufacturer&#39;s instructions when using other collection tubes.</li>
	<li>After centrifugation, the plasma supernatant will appear clear and yellowish. Check whether the sample shows signs of hemolysis (Figure 3) and transfer the plasma (supernatant) to a 15 mL centrifuge tube without disturbing the cellular layer using a disposable serological pipette (or disposable bulb pipette or p1000 pipettes with filter tip). Leave a small residual volume of plasma above the cell layer (approximately 5 mm).</li>
	<li>If hemolysis is observed, discard the sample for further analyses. (Figure 5). See the troubleshooting section in the Discussion to assess hemolysis.</li>
	<li>Centrifuge the plasma in a 15 mL centrifuge tube at RT (15 &#176;C-25 &#176;C) for 10-20 min at 3,000 (&#177;150) x g. Perform&#160;this step to remove any residual intact blood cells carried over from the first centrifugation step.</li>
	<li>After centrifugation, carefully remove the tube from the centrifuge and transfer 1-4 mL of plasma to 1-4 mL polypropylene cryogenic vials using a disposable serological pipette (or disposable bulb pipette or p1000 pipettes with filter tip). A residual volume of plasma (approximately 0.3 mL or 7 mm height) must be left at the bottom of the tube to avoid contaminating the plasma with blood cells (Figure 5).</li>
	<li>Immediately freeze the plasma upright in the storage box at -80 &#176;C and record the time of sample storage. Verify that the samples were processed within the required 4 h time frame.</li>
	<li>Collect the cellular layer (buffy coat) using a P1000 and filtered tip and transfer it to a 2 mL tube. Immediately freeze and store at -80 &#176;C.</li>
</ol>

<ol><li>Alix-Panabières, C., Pantel, K. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Clinical+applications+of+circulating+tumor+cells+and+circulating+tumor+DNA+as+liquid+biopsy%5BTitle%5D)+AND+%22Cancer+Discovery%22%5BJournal%5D)">Clinical applications of circulating tumor cells and circulating tumor DNA as liquid biopsy.</a> Cancer Discovery. 6 (5), 479-491 (2016).</li>
<li>Zhou, B., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Application+of+exosomes+as+liquid+biopsy+in+clinical+diagnosis%5BTitle%5D)+AND+%22Signal+Transduction+and+Targeted+Therapy%22%5BJournal%5D)">Application of exosomes as liquid biopsy in clinical diagnosis.</a> Signal Transduction and Targeted Therapy. 5 (1), 144(2020).</li>
<li>Bettegowda, C., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Liquid+biopsies%3A+Genotyping+circulating+tumor+DNA%5BTitle%5D)+AND+%22Nature+Medicine%22%5BJournal%5D)">Liquid biopsies: Genotyping circulating tumor DNA.</a> Nature Medicine. 4 (6), (2014).</li>
<li>Heitzer, E., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Recommendations+for+a+practical+implementation+of+circulating+tumor+DNA+mutation+testing+in+metastatic+non-small-cell+lung+cancer%5BTitle%5D)+AND+%22ESMO+Open%22%5BJournal%5D)">Recommendations for a practical implementation of circulating tumor DNA mutation testing in metastatic non-small-cell lung cancer.</a> ESMO Open. 7 (2), 100399(2022).</li>
<li>Gennari, A., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((ESMO+Clinical+Practice+Guideline+for+the+diagnosis%2C+staging+and+treatment+of+patients+with+metastatic+breast+cancer%5BTitle%5D)+AND+%22Annals+of+Oncology%3A+Official+Journal+of+the+European+Society+for+Medical+Oncology%22%5BJournal%5D)">ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer.</a> Annals of Oncology: Official Journal of the European Society for Medical Oncology. 32 (12), 1475-1495 (2021).</li>
<li>Van Buren, T., Arwatz, G., Smits, A. J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((A+simple+method+to+monitor+hemolysis+in+real+time%5BTitle%5D)+AND+%22Scientific+Reports%22%5BJournal%5D)">A simple method to monitor hemolysis in real time.</a> Scientific Reports. 10 (1), 5101(2020).</li>
<li>Ignatiadis, M., Sledge, G. W., Jeffrey, S. S. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Liquid+biopsy+enters+the+clinic+-+implementation+issues+and+future+challenges%5BTitle%5D)+AND+%22Nature+Reviews.+Clinical+Oncology%22%5BJournal%5D)">Liquid biopsy enters the clinic - implementation issues and future challenges.</a> Nature Reviews. Clinical Oncology. 18 (5), 297-312 (2021).</li>
<li>Sidstedt, M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Inhibition+mechanisms+of+hemoglobin%2C+immunoglobulin+G%2C+and+whole+blood+in+digital+and+real-time+PCR%5BTitle%5D)+AND+%22Analytical+and+Bioanalytical+Chemistry%22%5BJournal%5D)">Inhibition mechanisms of hemoglobin, immunoglobulin G, and whole blood in digital and real-time PCR.</a> Analytical and Bioanalytical Chemistry. 410 (10), 2569-2583 (2018).</li>
<li>Maass, K. K., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((From+sampling+to+sequencing%3A+A+liquid+biopsy+pre-analytic+workflow+to+maximize+multi-layer+genomic+information+from+a+single+tube%5BTitle%5D)+AND+%22Cancers%22%5BJournal%5D)">From sampling to sequencing: A liquid biopsy pre-analytic workflow to maximize multi-layer genomic information from a single tube.</a> Cancers. 13 (12), 3002(2021).</li>
<li>Greytak, S. R., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Harmonizing+cell-free+DNA+collection+and+processing+practices+through+evidence-based+guidance%5BTitle%5D)+AND+%22Clinical+Cancer+Research%3A+An+Official+Journal+of+the+American+Association+for+Cancer+Research%22%5BJournal%5D)">Harmonizing cell-free DNA collection and processing practices through evidence-based guidance.</a> Clinical Cancer Research: An Official Journal of the American Association for Cancer Research. 26 (13), 3104-3109 (2020).</li>
<li>Trigg, R. M., Martinson, L. J., Parpart-Li, S., Shaw, J. A. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Factors+that+influence+quality+and+yield+of+circulating-free+DNA%3A+A+systematic+review+of+the+methodology+literature%5BTitle%5D)+AND+%22Heliyon%22%5BJournal%5D)">Factors that influence quality and yield of circulating-free DNA: A systematic review of the methodology literature.</a> Heliyon. 4 (7), 00699(2018).</li>
<li>Boissier, E., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((The+centrifuge+brake+impacts+neither+routine+coagulation+assays+nor+platelet+count+in+platelet-poor+plasma%5BTitle%5D)+AND+%22Clinical+Chemistry+and+Laboratory+Medicine%22%5BJournal%5D)">The centrifuge brake impacts neither routine coagulation assays nor platelet count in platelet-poor plasma.</a> Clinical Chemistry and Laboratory Medicine. 58 (9), 185-188 (2020).</li>
<li>Johansson, G., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Considerations+and+quality+controls+when+analyzing+cell-free+tumor+DNA%5BTitle%5D)+AND+%22Biomolecular+Detection+and+Quantification%22%5BJournal%5D)">Considerations and quality controls when analyzing cell-free tumor DNA.</a> Biomolecular Detection and Quantification. 17, 100078(2019).</li>
<li>Casas-Arozamena, C., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Genomic+profiling+of+uterine+aspirates+and+cfDNA+as+an+integrative+liquid+biopsy+strategy+in+endometrial+cancer%5BTitle%5D)+AND+%22Journal+of+Clinical+Medicine%22%5BJournal%5D)">Genomic profiling of uterine aspirates and cfDNA as an integrative liquid biopsy strategy in endometrial cancer.</a> Journal of Clinical Medicine. 9 (2), 585(2020).</li>
<li>Alcoceba, M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Liquid+biopsy%3A+a+non-invasive+approach+for+Hodgkin+lymphoma+genotyping%5BTitle%5D)+AND+%22British+Journal+of+Haematology%22%5BJournal%5D)">Liquid biopsy: a non-invasive approach for Hodgkin lymphoma genotyping.</a> British Journal of Haematology. 195 (4), 542-551 (2021).</li>
<li>Szpechcinski, A., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Cell-free+DNA+levels+in+plasma+of+patients+with+non-small-cell+lung+cancer+and+inflammatory+lung+disease%5BTitle%5D)+AND+%22British+Journal+of+Cancer%22%5BJournal%5D)">Cell-free DNA levels in plasma of patients with non-small-cell lung cancer and inflammatory lung disease.</a> British Journal of Cancer. 113 (3), 476-483 (2015).</li>
<li>Earl, J., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Somatic+mutation+profiling+in+the+liquid+biopsy+and+clinical+analysis+of+hereditary+and+familial+pancreatic+cancer+cases+reveals+kras+negativity+and+a+longer+overall+survival%5BTitle%5D)+AND+%22Cancers%22%5BJournal%5D)">Somatic mutation profiling in the liquid biopsy and clinical analysis of hereditary and familial pancreatic cancer cases reveals kras negativity and a longer overall survival.</a> Cancers. 13 (7), 1612(2021).</li>
<li>Lampignano, R., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Multicenter+evaluation+of+circulating+cell-free+DNA+extraction+and+downstream+analyses+for+the+development+of+standardized+%28pre%29analytical+work+flows%5BTitle%5D)+AND+%22Clinical+Chemistry%22%5BJournal%5D)">Multicenter evaluation of circulating cell-free DNA extraction and downstream analyses for the development of standardized (pre)analytical work flows.</a> Clinical Chemistry. 66 (1), 149-160 (2020).</li>
<li>Febbo, P. G., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Minimum+technical+data+elements+for+liquid+biopsy+data+submitted+to+public+databases%5BTitle%5D)+AND+%22Clinical+Pharmacology+and+Therapeutics%22%5BJournal%5D)">Minimum technical data elements for liquid biopsy data submitted to public databases.</a> Clinical Pharmacology and Therapeutics. 107 (4), 730-734 (2020).</li>
<li>De Mattos-Arruda, L., Siravegna, G. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((How+to+use+liquid+biopsies+to+treat+patients+with+cancer%5BTitle%5D)+AND+%22ESMO+Open%22%5BJournal%5D)">How to use liquid biopsies to treat patients with cancer.</a> ESMO Open. 6 (2), 100060(2021).</li>
</ol>

Beatriz Bellosillo (BB): BB received honoraria for speaker, consultancy or advisory role from Amgen, Astra-Zeneca, Biocartis, Janssen, Merck-Serono, Novartis, Qiagen, Roche Diagnostics, Roche Pharma, ThermoFisher, Pfizer and BMS. Sara L&#243;pez-Tarruella (SL): SL received honoraria for speaker, consultancy or advisory role from Astra-Zeneca/Daiichi-Sankyo, MSD, Novartis, Pfizer, Roche Pharma, Gilead, Lilly, Pierre Fabre, Seagen, GlaxoSmithKline, and Veracyte. Noelia Tarazona (NT): NT received honoraria for speaker, consultancy, or advisory role from Amgen, Pfizer, Merck-Serono, Servier, SEOM, and ESMO. Javier Hernandez-Losa (JHL): received honoraria for speaker, consultancy, or advisory role from Astra-Zeneca, Janssen, Novartis, Roche Diagnostics, Roche Pharma, ThermoFisher, Lilly and Diaceutics. Rodrigo Toledo (RT) reports receiving research grants related to this study from Novartis and research grants unrelated to this study from AstraZeneca and Beigene. The remaining authors have no disclosures with regard to the manuscript.

The liquid biopsy has numerous potential applications at different times during the management of cancer. First, at diagnosis to identify tumor molecular markers that would suggest the presence of a potential tumor lesion that might be further investigated clinically. Second, during treatment for real-time monitoring of the disease, assessment of treatment molecular response, clonal evolution, and early detection of disease relapses or treatment resistance. Finally, after the surgical treatment, as a tool for the detecti...

The term "liquid biopsy" was defined in 20101 as the presence of molecules (e.g., protein, deoxyribonucleic acid (DNA), ribonucleic acid (RNA)), cells, or extracellular vesicles (e.g., exosomes) in blood and other bodily fluids that originate from the primary tumor. The use of liquid biopsy samples has revolutionized translational oncology research as tissue biopsies, limited to a particular region at a particular moment, may miss relevant clones due to tumor heterogeneity. In addition, liquid biopsy plays a relevant role in tumor types where primary tissue is scarce or not accessible, as it may avoid an invasive biopsy, reducing costs and risk to patients. Furthermore, the tumor molecular characteristics are constantly evolving mainly due to the therapy pressure, and liquid biopsy samples can capture the tumor clonal dynamics as they can be taken longitudinally, in different clinical and therapeutic times of the disease such as baseline, on treatment, best response, and at disease progression or even before. The concept of the "real-time liquid biopsy" means that dynamic changes in the tumor can be monitored in real-time, thus allowing precision medicine in this disease. The liquid biopsy has numerous potential applications in the clinic, including screening and early detection of cancer, real-time monitoring of disease, detection of minimal residual disease, studying mechanisms for treatment resistance, and stratification of patients at the therapeutic level1. The early detection of disease recurrence and progression are an unmet clinical need in many tumor types and is a key factor in increasing the survival and quality of life of cancer patients. Routine imaging modalities and soluble tumor markers may lack the sensitivity and/or specificity required for this task. Thus, novel predictive markers are urgently needed in the clinic, such as those based on circulating free nucleic acids.
The types of samples that are used for liquid biopsy studies include but are not limited to blood, urine, saliva, and stool samples. Other tumor-specific samples can be cell aspirates, cerebrospinal fluid, pleural fluid, cyst and ascites fluid, sputum, and pancreatic juice2. The former liquids may contain different types of cancer-derived materials, circulating tumor cells (CTC), or fragments such as exosomes and cell-free circulating tumor DNA (ctDNA). Nucleic acids may be encapsulated in extracellular vesicles (EVs) or released into body fluids due to cell death and damage. Circulating free DNA (cfDNA) is mainly released into the bloodstream from apoptotic or necrotic cells and is present in all individuals, showing increased levels in inflammatory or oncological diseases3. Exosomes are small extracellular vesicles (~30-150 nm) secreted by cells containing nucleic acids, proteins, and lipids. These vesicles form part of the intercellular communication network and are commonly found in many types of body fluids2. The nucleic acids enclosed inside EVs are protected from the harsh environment within bodily fluids, thus providing a more robust way to study these molecules in the liquid biopsy setting.
Overall, the levels of circulating nucleic acids in liquid biopsy samples are very low, and therefore sensitive methods are needed for detection, such as digital PCR or next-generation sequencing (NGS). Preanalytical management of the sample is crucial to prevent blood cell lysis and release of intact DNA, causing contamination of the cfDNA with the genomic DNA. Furthermore, care must be taken when extracting samples to avoid the presence of inhibitors of enzyme-based analysis methods.
Here we present a standardized method for the collection and storage of plasma and serum samples, which is a crucial first step for liquid biopsy-based downstream applications, including circulating nucleic acid analyses.

<table><tbody><tr><td>1.5 mL Eppendorf tubes</td><td>Eppendorf</td><td>0030 120.086</td><td>Any standard tubes/equipment can be used</td></tr><tr><td>10 mL serological disposable pipettes</td><td>BIOFIL</td><td>GSP010010</td><td>Any standard tubes/equipment can be used</td></tr><tr><td>10 mL Vacutainer K2 EDTA tube</td><td>Becton Dickinson</td><td>367525</td><td>These tubes can be used for plasma collection</td></tr><tr><td>15 mL polypropylene centrifuge tubes</td><td>BIOFIL</td><td>CFT411150</td><td>Any standard tubes/equipment can be used</td></tr><tr><td>3.5 mL BD Vacutainer tube without anticoagulant</td><td>Becton Dickinson</td><td>368965</td><td>Either 8.5 or 3.5 mL tubes can be used for serum collection</td></tr><tr><td>4 mL polypropylene cryogenic vial, round bottom, self-standing</td><td>Corning</td><td>430662</td><td>Any standard tubes/equipment can be used</td></tr><tr><td>4 mL Vacutainer K2 EDTA tube</td><td>Becton Dickinson</td><td>367864</td><td>These tubes can be used for plasma collection</td></tr><tr><td>4200 TapeStation System</td><td>Agilent</td><td>G2991BA</td><td>Several quantification methods are available with a&amp;nbsp; specific application for cfDNA</td></tr><tr><td>5 mL serological disposable pipettes</td><td>BIOFIL</td><td>GSP010005</td><td>Any standard tubes/equipment can be used</td></tr><tr><td>8.5 mL BD Vacutainer tube without anticoagulant</td><td>Becton Dickinson</td><td>366468</td><td>Either 8.5 or 3.5 mL tubes can be used for serum collection</td></tr><tr><td>Centrifuge, capable of ~3000 x &lt;em&gt;g&lt;/em&gt; with a swing bucket rotor</td><td>Thermo Fisher Scientific</td><td>Sorvall ST 16 &amp;nbsp;10688725</td><td>Any standard tubes/equipment can be used</td></tr><tr><td>Freezer storage boxes for 1&amp;ndash;4 mLcryogenic vials</td><td>Corning</td><td>431120</td><td>These boxes are needed when using 4 mL vials for storage</td></tr><tr><td>p1000 pipette tips</td><td>CORNING</td><td>4809</td><td>Any standard tubes/equipment can be used</td></tr><tr><td>QIAamp Circulating Nucleic Acid Kit</td><td>Qiagen</td><td>55114</td><td>Any commercially available kit that is specific for cfDNA isolation can be used with this blood prcessing protocol.</td></tr><tr><td>Streck&amp;nbsp;Cell-Free DNA BCT CE tubes 10 mL</td><td>Streck</td><td>218997</td><td>These tubes can be used for plasma collection</td></tr><tr><td>Temperature Freezer (-80 &amp;deg;C)</td><td>ESCO</td><td>2180104</td><td>Any standard tubes/equipment can be used</td></tr></tbody></table>

a standardized liquid biopsy preanalytical protocol for downstream circulating-free dna applications

A Standardized Liquid Biopsy Preanalytical Protocol for Downstream Circulating-Free DNA Applications

The term liquid biopsy (LB) refers to molecules such as proteins, DNA, RNA, cells, or extracellular vesicles in blood and other bodily fluids that originate from the primary and/or metastatic tumor. LB has emerged as a mainstay in translational research and has started to become part of clinical oncology practice, providing a minimally invasive alternative to solid biopsy. The LB allows real-time monitoring of a tumor via a minimally invasive sample extraction, such as blood. The applications include early cancer detection, patient follow-up for the detection of disease progression, assessment of minimal residual disease, and potential identification of molecular progression and mechanism of resistance. In order to achieve a reliable analysis of these samples that can be reported in the clinic, the preanalytical procedures should be carefully considered and strictly followed. Sample collection, quality, and storage are crucial steps that determine their usefulness in downstream applications. Here, we present standardized protocols from our liquid biopsy working module for collecting, processing, and storing plasma and serum samples for downstream liquid biopsy analysis based on circulating-free DNA. The protocols presented here require standard equipment and are sufficiently flexible to be applied in most laboratories focused on biological procedures.

After centrifugation of the blood tubes without anticoagulant, the upper phase appears a pale yellow and corresponds to the serum fraction (Figure 2). This fraction is carefully removed and aliquoted for subsequent analysis.
Hemolysis may be present in either the plasma or serum fraction, and the upper phase will have a reddish appearance, which indicates the presence and degree of hemolysis (Figure 3).
Aft...

The liquid biopsy has revolutionized our approach to oncology translational studies, with sample collection, quality, and storage being crucial steps for its successful clinical application. Here we describe a standardized and validated protocol for downstream circulating-free DNA applications that can be applied in most translational research laboratories.

The term liquid biopsy (LB) refers to molecules such as proteins, DNA, RNA, cells, or extracellular vesicles in blood and other bodily fluids that ...

a-standardized-liquid-biopsy-preanalytical-protocol-for-downstream

Research

JoVE Journal

Cancer Research

This video describes a silica-based membrane procedure to isolate circulating cell-free DNA or cfDNA from human plasma sample. The cfDNA is a promising biomarker for cancer diagnosis and...

Isolation of Circulating Cell-free DNA (cfDNA): A Silica-based Membrane Procedure to Extract cfDNA from Blood Plasma of Cancer Patients

This manuscript describes clinical protocols for two next-generation sequencing panels. One panel interrogates hematologic malignancies while the other panel targets genes commonly mutated in solid tumors. Molecular classification of driver mutations in human malignancies offers valuable prognostic and predictive information.

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

An integrated system for targeted next-generation sequencing of oncology specimens is described. This cross-platform system is optimized for low-quality and low-quantity tumor biopsies, accommodates low DNA inputs, includes well-characterized multi-variant controls, and features a novel variant caller that is informed by quantitative pre-analytical quality control measures.

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Here, we present the detailed protocol adopted in the BioMILD screening trial to perform the circulating microRNA signature classifier test for early lung cancer detection.

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier (MSC) for Lung Cancer Screening

Detection of circulating ribonucleic acid (cRNA) from blood is an unmet need in clinical diagnostics. Here we describe methods that characterize cRNA from non-small cell lung cancer patients using sensitive and specific digital polymerase chain reaction. The tests meet design requirements to detect fusion variants within 72 hours.

A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction

Here, we present a protocol to accurately quantify multiple genetic alterations of a target region in a single reaction using drop-off ddPCR and a unique pair of hydrolysis probes.

Single Droplet Digital Polymerase Chain Reaction for Comprehensive and Simultaneous Detection of Mutations in Hotspot Regions

Here, we present a protocol to detect tumor somatic mutations in circulating DNA present in patient biological fluids (biofluids). Our droplet digital polymerase chain reaction (dPCR)-based method enables quantification of the tumor mutation allelic frequency (MAF), facilitating a minimally invasive complement to diagnosis and temporal monitoring of tumor response.

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids

This protocol details clinically implementable preparation of high quality PBMC and plasma biosamples at the clinical trial site that can be used for translational biomarker analysis.

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis

In this paper we present a detailed protocol for non-invasive liquid biopsy technique, including blood collection, plasma and buffy coat separation, cfDNA and germline DNA extraction, quantification of cfDNA or germline DNA, and cfDNA fragment enrichment analysis.

Detection of Cell-Free DNA in Blood Plasma Samples of Cancer Patients

This paper describes the application of automated equipment to easily and efficiently separate and collect substances, such as cell-free DNA and circulating tumor cells, from whole blood.

Automatic Separation and Collection of Cancer-Related Substances from Clinical Samples

Here we present a protocol to illustrate the isolation of rare cancer cells from a contrived sample containing whole blood and spiked in lung cancer cells. The protocol utilizes a semi-automated, label-free cell isolation platform. Enriched cells are subsequently analyzed for epidermal growth factor receptor mutations using droplet digital PCR.

Profiling Epidermal Growth Factor Receptor DNA Mutations in Circulating Rare Cells Using a Cell Isolation System and Droplet Digital PCR

Learn a standardized liquid biopsy protocol for processing and storing blood samples for circulating free DNA applications in oncology research. This method reduces variability and enhances precision in clinical outcomes.

A Standardized Liquid Biopsy Preanalytical Protocol for Downstream Circulating-Free DNA Applications

Explore More Videos